首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Management of menopause 更年期的管理
Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-24 DOI: 10.18773/austprescr.2023.014
Karen Magraith, Christina Jang
SUMMARY During perimenopause and after menopause, women may experience diverse symptoms. All women require a comprehensive assessment of their current health and risks for future disease, appropriate screening, and promotion of a healthy lifestyle. Menopausal hormone therapy is the most effective treatment for menopausal symptoms. It can be offered to symptomatic patients with no contraindications following an individualised discussion about the risk of harms versus benefits. Menopausal hormone therapy is recommended for women with premature ovarian insufficiency (menopause occurring before 40 years of age) regardless of symptoms, unless contraindicated. Nonhormonal medications may improve symptoms for women who have contraindications to, or do not wish to take, menopausal hormone therapy.
{"title":"Management of menopause","authors":"Karen Magraith, Christina Jang","doi":"10.18773/austprescr.2023.014","DOIUrl":"https://doi.org/10.18773/austprescr.2023.014","url":null,"abstract":"SUMMARY During perimenopause and after menopause, women may experience diverse symptoms. All women require a comprehensive assessment of their current health and risks for future disease, appropriate screening, and promotion of a healthy lifestyle. Menopausal hormone therapy is the most effective treatment for menopausal symptoms. It can be offered to symptomatic patients with no contraindications following an individualised discussion about the risk of harms versus benefits. Menopausal hormone therapy is recommended for women with premature ovarian insufficiency (menopause occurring before 40 years of age) regardless of symptoms, unless contraindicated. Nonhormonal medications may improve symptoms for women who have contraindications to, or do not wish to take, menopausal hormone therapy.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135220377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Drug: Elasomeran+davesomeran for prevention of COVID-19 预防COVID-19的新药:Elasomeran+davesomeran
Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-24 DOI: 10.18773/austprescr.2023.018
{"title":"New Drug: Elasomeran+davesomeran for prevention of COVID-19","authors":"","doi":"10.18773/austprescr.2023.018","DOIUrl":"https://doi.org/10.18773/austprescr.2023.018","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"61 11","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135220371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 vaccines in 2023 2023年的COVID-19疫苗
Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-24 DOI: 10.18773/austprescr.2023.020
Ketaki Sharma, Jean Li-Kim-Moy
SUMMARY Most Australian adults now have hybrid immunity to the SARS-CoV-2 virus, referring to a combination of protection from previous vaccine doses and past infection. Protection from both vaccination and past infection wanes over time. Booster doses are recommended to ensure that those who are at increased risk of severe COVID-19 remain protected. The optimal timing of future booster doses to maintain adequate protection against severe illness is not yet known. Older age remains the most important risk factor for severe COVID-19, including in the current Omicron variant era. The original COVID-19 vaccines are monovalent vaccines based on the ancestral strain of the SARS-CoV-2 virus. Bivalent vaccines have been developed based on earlier Omicron subvariants (BA.1 or BA.4-5) and the ancestral strain. These provide enhanced protection against severe illness from Omicron compared with the original monovalent vaccines. Updated monovalent vaccines based on a more recent Omicron subvariant (XBB.1.5) have been developed. COVID-19 vaccines have an excellent safety record, and serious adverse events are extremely rare.
{"title":"COVID-19 vaccines in 2023","authors":"Ketaki Sharma, Jean Li-Kim-Moy","doi":"10.18773/austprescr.2023.020","DOIUrl":"https://doi.org/10.18773/austprescr.2023.020","url":null,"abstract":"SUMMARY Most Australian adults now have hybrid immunity to the SARS-CoV-2 virus, referring to a combination of protection from previous vaccine doses and past infection. Protection from both vaccination and past infection wanes over time. Booster doses are recommended to ensure that those who are at increased risk of severe COVID-19 remain protected. The optimal timing of future booster doses to maintain adequate protection against severe illness is not yet known. Older age remains the most important risk factor for severe COVID-19, including in the current Omicron variant era. The original COVID-19 vaccines are monovalent vaccines based on the ancestral strain of the SARS-CoV-2 virus. Bivalent vaccines have been developed based on earlier Omicron subvariants (BA.1 or BA.4-5) and the ancestral strain. These provide enhanced protection against severe illness from Omicron compared with the original monovalent vaccines. Updated monovalent vaccines based on a more recent Omicron subvariant (XBB.1.5) have been developed. COVID-19 vaccines have an excellent safety record, and serious adverse events are extremely rare.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"39 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135220372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Latest News: Update on changing Australian medicine names 最新消息:更改澳大利亚药品名称的最新情况
Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-24 DOI: 10.18773/austprescr.2023.016
{"title":"Latest News: Update on changing Australian medicine names","authors":"","doi":"10.18773/austprescr.2023.016","DOIUrl":"https://doi.org/10.18773/austprescr.2023.016","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135220376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Drug: Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria 新药:芬纳酮治疗2型糖尿病伴蛋白尿的慢性肾病
Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-24 DOI: 10.18773/austprescr.2023.017
{"title":"New Drug: Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria","authors":"","doi":"10.18773/austprescr.2023.017","DOIUrl":"https://doi.org/10.18773/austprescr.2023.017","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"7 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135220373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital health and prescribing: declare the past, diagnose the present, foretell the future. 数字医疗与处方:宣告过去,诊断现在,预言未来。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-01 DOI: 10.18773/austprescr.2023.015
Jodie A Austin, Michael A Barras, Clair M Sullivan
{"title":"Digital health and prescribing: declare the past, diagnose the present, foretell the future.","authors":"Jodie A Austin, Michael A Barras, Clair M Sullivan","doi":"10.18773/austprescr.2023.015","DOIUrl":"10.18773/austprescr.2023.015","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"46 3","pages":"46-47"},"PeriodicalIF":2.7,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prescribing and peritoneal dialysis. 处方和腹膜透析
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.001
Frank Reimann, Melinda Tomlins

Peritoneal dialysis is a home-based therapy for patients with end-stage kidney disease. It is less efficient in removing solutes and fluid than haemodialysis but offers more flexibility and independence. Peritoneal transport characteristics affect the dialysis prescription. The timing of drug administration is independent of the dialysis process except for the administration of intraperitoneal antibiotics. Dose reductions should follow current recommendations for patients with kidney disease. Fluid overload is common in patients undergoing peritoneal dialysis. Residual kidney function can ameliorate this problem and needs to be preserved. Dialysis solutions with high glucose concentrations contribute to adverse metabolic effects. Peritoneal dialysis-related catheter complications and infections may require patients to transition to haemodialysis. Antifungal prophylaxis needs to be co-administered for the duration of antibiotic courses for any indication to reduce the risk of fungal peritonitis. Close communication with the patient's supervising dialysis unit is required.

腹膜允许溶质和水在血管和腹膜间隙之间运动。其运输特性通过平衡测试进行评估,可分为低、低平均、高平均和高8低转运蛋白患者需要更长的停留时间,而高转运蛋白患者通常需要更短的停留时间。传输特性会随着时间的推移而改变,而这一过程最终往往会失败。
{"title":"Prescribing and peritoneal dialysis.","authors":"Frank Reimann, Melinda Tomlins","doi":"10.18773/austprescr.2023.001","DOIUrl":"10.18773/austprescr.2023.001","url":null,"abstract":"<p><p>Peritoneal dialysis is a home-based therapy for patients with end-stage kidney disease. It is less efficient in removing solutes and fluid than haemodialysis but offers more flexibility and independence. Peritoneal transport characteristics affect the dialysis prescription. The timing of drug administration is independent of the dialysis process except for the administration of intraperitoneal antibiotics. Dose reductions should follow current recommendations for patients with kidney disease. Fluid overload is common in patients undergoing peritoneal dialysis. Residual kidney function can ameliorate this problem and needs to be preserved. Dialysis solutions with high glucose concentrations contribute to adverse metabolic effects. Peritoneal dialysis-related catheter complications and infections may require patients to transition to haemodialysis. Antifungal prophylaxis needs to be co-administered for the duration of antibiotic courses for any indication to reduce the risk of fungal peritonitis. Close communication with the patient's supervising dialysis unit is required.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"1 1","pages":"5-8"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41407428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Prescriber: a new chapter. 澳大利亚处方集:新篇章。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-06-01 DOI: 10.18773/austprescr.2023.008
Leigh-Anne Claase
{"title":"<i>Australian Prescriber</i>: a new chapter.","authors":"Leigh-Anne Claase","doi":"10.18773/austprescr.2023.008","DOIUrl":"10.18773/austprescr.2023.008","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"46 1","pages":"2"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood pressure elevations in hospital. 医院血压升高。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.068
Arduino A Mangoni, Elzbieta A Jarmuzewska, Genevieve M Gabb, Patrick Russell

Long-term hypertension control in the community significantly reduces cardiovascular risk. However, the benefit of controlling acute elevations of blood pressure in hospitalised patients is unclear. In-hospital elevations of blood pressure are relatively common and might not reflect poorly controlled blood pressure before admission. The measurement of blood pressure in hospital patients significantly differs from the best practice recommended for primary care and outpatients. Recent observational studies suggest that the pharmacological treatment of acute, asymptomatic, in-hospital elevations of blood pressure may have no benefit. However, it may increase the risk of in-hospital and post-discharge complications. Pending the development of robust inpatient measurement protocols, acute blood pressure elevations in hospitalised patients should not routinely require antihypertensive treatment in the absence of symptoms or acute end-organ damage. Rather, such elevations should facilitate follow-up of blood pressure and other cardiovascular risk factors after discharge.

长期控制社区高血压可显著降低心血管风险。然而,控制住院患者急性血压升高的益处尚不清楚。院内血压升高相对常见,可能并不反映入院前血压控制不良。医院患者的血压测量与推荐给初级保健和门诊患者的最佳实践有很大不同。最近的观察性研究表明,药物治疗急性,无症状,院内血压升高可能没有好处。然而,它可能会增加院内和出院后并发症的风险。在制定健全的住院患者测量方案之前,在没有症状或急性终末器官损伤的情况下,住院患者的急性血压升高不应常规要求降压治疗。相反,这种升高应该有利于出院后血压和其他心血管危险因素的随访。
{"title":"Blood pressure elevations in hospital.","authors":"Arduino A Mangoni,&nbsp;Elzbieta A Jarmuzewska,&nbsp;Genevieve M Gabb,&nbsp;Patrick Russell","doi":"10.18773/austprescr.2022.068","DOIUrl":"https://doi.org/10.18773/austprescr.2022.068","url":null,"abstract":"<p><p>Long-term hypertension control in the community significantly reduces cardiovascular risk. However, the benefit of controlling acute elevations of blood pressure in hospitalised patients is unclear. In-hospital elevations of blood pressure are relatively common and might not reflect poorly controlled blood pressure before admission. The measurement of blood pressure in hospital patients significantly differs from the best practice recommended for primary care and outpatients. Recent observational studies suggest that the pharmacological treatment of acute, asymptomatic, in-hospital elevations of blood pressure may have no benefit. However, it may increase the risk of in-hospital and post-discharge complications. Pending the development of robust inpatient measurement protocols, acute blood pressure elevations in hospitalised patients should not routinely require antihypertensive treatment in the absence of symptoms or acute end-organ damage. Rather, such elevations should facilitate follow-up of blood pressure and other cardiovascular risk factors after discharge.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 6","pages":"205-207"},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/e7/austprescr-45-205.PMC9722348.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Erratum: Bariatric surgery and medicines [Correction]. 更正:减肥手术和药物[更正]。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.074

[This corrects the article on p. 162 in vol. 45, PMID: 36382169.].

[这更正了第45卷第162页的文章,PMID: 36382169]。
{"title":"Erratum: Bariatric surgery and medicines [Correction].","authors":"","doi":"10.18773/austprescr.2022.074","DOIUrl":"https://doi.org/10.18773/austprescr.2022.074","url":null,"abstract":"<p><p>[This corrects the article on p. 162 in vol. 45, PMID: 36382169.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 6","pages":"219"},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/65/austprescr-45-219.PMC9722356.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1